Blood and platelet transfusion from a donor with presymptomatic Covid-19
- PDF / 153,279 Bytes
- 2 Pages / 595.276 x 790.866 pts Page_size
- 19 Downloads / 168 Views
LETTER TO THE EDITOR
Blood and platelet transfusion from a donor with presymptomatic Covid-19 Konstantinos Liapis 1 & Menelaos Papoutselis 1 & Georgios Vrachiolias 1 & Christina Misidou 1 & Emmanouil Spanoudakis 1 & Zoe Bezirgiannidou 1,2 & Aikaterini Pentidou 1 & Theocharis Konstantinidis 2,3 & Ioannis Kotsianidis 1 Received: 26 October 2020 / Accepted: 2 November 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Dear Editor, The Covid-19 pandemic has major implications for blood transfusion. Because SARS-CoV-2 is a new virus, its potential for transfusion transmission, including by an asymptomatic or presymptomatic donor, is uncertain [1]. The risk for transmitting other coronaviruses including SARS-CoV by transfusion is currently considered low [1, 2]. SARS-CoV-2 RNA has been detected in the bloodstream of infected individuals [3, 4], but it is unknown whether this may translate to transmissibility. Data relating to the number of blood donors with presymptomatic infection when donating are limited [5], and therefore, an effort to collect data is important to determine whether transfusions carry a risk of transmission. We report the transfusion of blood and platelets from a presymptomatic donor. The donor was a 48-year-old man who donated blood on August 12, 2020, at the Hippokration Blood Institute in Thessaloniki. At the time of donation, he had no symptoms of an infectious illness. According to the current blooddonation practice, he underwent screening for symptoms and elevated temperature before entering facilities and donation site. Donor blood was separated into red cells, platelets, and
This manuscript contains original material that has not been reported or published elsewhere or submitted previously to another journal. * Georgios Vrachiolias [email protected] 1
Department of Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace Medical School, Dragana Area, 681 00 Alexandroupolis, Greece
2
Blood Transfusion Institute, University Hospital of Alexandroupolis, Alexandroupolis, Greece
3
Laboratory of Molecular Hematology, Department of Medicine, Democritus University of Thrace Medical School, Alexandroupolis, Greece
plasma. The red-blood-cell unit was transfused in Thessaloniki on August 14 and the platelet unit was transfused in Alexandroupolis on August 17, with no adverse reactions. Patient 1, who received the red-cell transfusion, was an 86year-old woman admitted to the hospital because of anemia. Patient 2, who received the platelet unit, was a 61-year-old man who had been diagnosed with myelodysplastic syndrome in February 2017. He achieved complete remission with azacitidine but disease relapsed and underwent unrelateddonor hematopoietic-cell transplantation in October 2018. He again relapsed in July 2019, and at the time of transfusion, he was treated with azacitidine and glasdegib. On August 20, the Hippokration Blood Institute was notified about a positive nasopharyngeal SARS-CoV-2 test in the donor. The donor was evaluated on August
Data Loading...
